Targeting CGRP signaling reverses maladaptive neurogenic immunosuppression in head and neck squamous cell carcinoma models

Paper. Idlett-Ali SL, Nguyen AT, Abdelazeem KN et al.. The Journal of Clinical Investigation, 19 Nov 2026.

Tags: Psilocybin, Cancer.

Weekly Science Digest, 13 Nov 2026 to 19 Nov 2026, finding 3: Psilocybin turns up as a CGRP inhibitor

High-dose psilocybin blocked CGRP signalling and slowed head and neck tumour growth in mice.

Cutting sensory nerve signalling reduced tumour growth in orthotopic models, and CGRP knockout plus radioimmunotherapy eradicated tumours. Psilocybin acted on the same pathway, transiently shrinking tumours by boosting antitumour immunity, with plasma correlations from single-dose human subjects.

How much weight it carries: Mouse tumour models plus in vitro work, with a correlational human plasma analysis; no clinical evidence that psilocybin affects cancer outcomes. (Mice, Preclinical, Mechanism, In vitro, Review)

Read the original

—
Node—
Statuslive
Throughput—